



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number

10/581,376

Filing Date

11/24/2004

First Named Inventor

Christopher Martin Bunce

Art Unit

N/A

Examiner Name

N/A

Attorney Docket Number

7492-104

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		<del>LUONG QUANG T ET AL., "Expression of Nm23-H1 in AML correlates with white cell count at diagnosis and in vitro acts as a survival factor for primary AMLs cells; evidence of a novel autocrine survival factor in AML," XP-001193730, Vol. 102 ( No. 11), (November 16, 2003). no source or pg.</del>	
/A.K./		OKABE-KADO JUNKO ET AL., "Physiological and pathological relevance of extracellular NM23/NDP kinases," Journal of Bioenergetics and Biomembranes, XP008031558, Vol. 35 ( No. 1), p. 89-93, (February 6, 2003).	
/A.K./		OKABE-KADO JUNKO ET AL., "Inhibitory action of nm23 proteins on induction of erythroid differentiation of human leukemia cells," Biochimica Et Biophysica Acta, XP008031891, Vol. 126 ( No. 2-3), p. 101-106, (1995). Vol. 126.	
/A.K./		OKABE-KADO J ET AL., "Identity of a differentiation inhibiting factor for mouse myeloid leukemia cells with NM23/nucleoside diphosphate kinase," XP008031856, Biochemical and Biophysical Research Communications, Vol. 182 ( No. 3), p. 987-994, (Feb 14, 1992).	
/A.K./		LOMBARDI DANIELA ET AL., "nm23: Unraveling its biological function in cell differentiation," Journal of Cellular Physiology, XP008031851, Vol. 182 ( No. 2), p. 144-149, (February 6, 2000).	
/A.K./		NEGRONI A ET AL., "Neuroblastoma specific effects of DR-nm23 and its mutant forms on differentiation and apoptosis," Cell Death and Differentiation, XP008031853, Vol. 7 ( No. 9), p. 843-850, (September 6, 2000).	
		<del>MUYAZAKI H ET AL., "Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture," Clinical Cancer Research: An official Journal of the American Association for Cancer Research, no date, vol., or pg.</del>	
/A.K./		WILLEMS ROEL ET AL., "Decrease in nucleoside diphosphate kinase (NDPK/nm 23) expression during hematopoietic maturation," Journal of Biological Chemistry, XP002285299, Vol. 273 ( No. 22), p. 13663-1366, (May 29, 1998).	
/A.K./		VENTURELLI D ET AL., "Overexpression of DR-NM23, a protein encoded by a member of the NM23 Gene Family, inhibits Granulocyte Differentiation and Induces Apoptosis in 32DC13 Myeloid Cells," Proceedings of the National Academy of Sciences of USA, National Academy of Science, XP002942044, p. 7435-7439, (August 6, 1995).	
/A.K./		GERVASI FABIO ET AL., "Nm23 Influences proliferation and differentiation of PC12 cells," Cell Growth and Differentiation, XP008031890, Vol. 7 ( No. 12), p. 1689-1695, (Dec 1996).	

Examiner Signature	/Aaron Kosar/	Date Considered	10/20/2009
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.K./